Beijing’s decision to approve the drug, its second developed abroad after Pfizer’s Paxlovid, comes amid domestic shortages of everything from fever-reducing medicines to antivirals that prevents severe disease. Read More
We współpracy z: https://fortune.com/2022/12/30/china-covid-wave-emergency-approval-merck-pill-lagevrio/
